Evidence map›Paper›PMID 29568219›Full record

ArticleBiomarker insights2018

Technical Validation of a Reverse-Transcription Quantitative Polymerase Chain Reaction In Vitro Diagnostic Test for the Determination of MiR-31-3p Expression Levels in Formalin-Fixed Paraffin-Embedded Metastatic Colorectal Cancer Tumor Specimens.

Lucas Ramon, Catherine David, Karine Fontaine, Elodie Lallet, Charles Marcaillou, Séverine Martin-Lannerée, Virginie Decaulne, Céline Vazart, Anne-Héloise Gélibert, Raouf Ben Abdelali and 5 more

Open access · goldAbstract read
In one paragraph

Article in Biomarker insights, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. MiR-31 as a predictive biomarker of cetuximab efficacy in metastatic colorectal cancer patients: systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Oncology reviews · 2020
    Article
  6. Article
  7. Article
  8. Review
  9. [Expression of miR-454-3p and its effect on proliferation, invasion and metastasis of colon cancer].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Lucas RamonIntegraGen SA, Evry, France.
Catherine DavidBiotika Ltda, São Paulo, Brazil.
Karine FontaineIntegraGen SA, Evry, France.
Elodie LalletIntegraGen SA, Evry, France.
Charles MarcaillouIntegraGen SA, Evry, France.
Séverine Martin-LanneréeIntegraGen SA, Evry, France.
Virginie DecaulneIntegraGen SA, Evry, France.
Céline VazartIntegraGen SA, Evry, France.
Anne-Héloise GélibertLaboratoire CERBA, Paris, France.
Raouf Ben AbdelaliLaboratoire CERBA, Paris, France.
Jean-Marc CostaLaboratoire CERBA, Paris, France.
Francis RousseauIntegraGen SA, Evry, France.
Raphaële ThiébautIntegraGen SA, Evry, France.
Larry YostIntegraGen, Inc., Cambridge, MA, USA.
Yann Gaston-MathéIntegraGen SA, Evry, France.
IntegraGen (France) · FRIntegra (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MiR-31-3p expression has been shown to be a predictive biomarker for response to anti-epithelial growth factor receptor therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). To aid in the quantification of miR-31-3p expression in formalin-fixed paraffin-embedded (FFPE) primary tumor samples from patients with mCRC, a reverse-transcription quantitative polymerase chain reaction (RT-qPCR) assay was developed and validated. Assay development included the identification of a microRNA reference standard and the determination of an appropriate relative quantification cutoff for differentiating low versus high miR-31-3p expression. Sample specimens for the validation studies included both FFPE slides and shavings. Polymerase chain reaction (PCR) efficiency and linearity, analytical sensitivity and specificity, assay robustness, reproducibility, and accuracy were demonstrated across a number of test conditions and differing quantitative PCR platforms. The data from this study provide evidence as to the feasibility of quantifying the expression of miR-31-3p from FFPE tumor tissue using a standardized RT-qPCR assay.

Indexed as

anti-EGFRbiomarkercetuximabMetastatic colorectal cancermiR-31-3pRT-qPCR

Identifiers

PMID29568219
PMCPMC5858679
OpenAlexW2793153498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.